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INTRODUCTION: Guidelines for surveillance after polypectomy are lacking in strong evidence. Our aim was to identify
some precursors of colorectal cancer lesions at 3 years after polypectomy to improve stratification and
surveillance programs.
METHODS: We included patients with high-risk lesions (HRLs), defined as advanced adenoma (AA), large serrated
polyps (SPs), and multiplicity (‡3 of any adenomas/SPs). Data on age, sex, cardiovascular risk factors,
pharmacological treatment, and the histological characteristics in each individual, and mutations in
genes involved in themost advanced index polyp, were collected. Parameters independently associated
with a metachronous HRL diagnosis were evaluated through univariate and multivariate analyses. The
results are reported as odds ratios and 95% confidence intervals along with P values.
RESULTS: A total of 537 cases (median age: 60.7 years; 66%male) were included. Dyslipidemia and smoking
correlated with metachronous HRLs. Multivariate logistic regression analysis showed that the
presence of multiplicity with ‡3 polyps on the index colonoscopy was significantly associated with
metachronous HRL, AA, proximal AA, and ‡3 polyps at 3 years. In addition, independent predictors
of metachronous proximal AA were increasing age, female sex, and the loss of expression of the
MLH1 protein.
DISCUSSION: Multiplicity was a strong predictor of HRLs at 3 years, although the inclusion of other clinical variables
(age, sex, smoking status, and dyslipidemia) improves surveillance recommendations. Without these
risk factors, the surveillance could be extended to 5 years; we propose examining the somatic
expression of MHL1 in all patients.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A498; http://links.lww.com/CTG/A499
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INTRODUCTION
Advanced adenomas (AAs), defined as having more than 25%
villous histology and/or a size $10 mm, and/or high-grade dys-
plasia, are the main precursor of colorectal cancer (CRC) (1,2).
Moreover, large serrated polyps (SPs) ($10 mm) are also con-
sidered equally premalignant lesions responsible for approxi-
mately 15% of CRC cases (3,4). Endoscopic polypectomy reduces
the incidence and mortality of CRC and remains the key to suc-
cessful population screening programs (2,5,6). Recent evidence
confirms that individuals with AA and/or large SPs have a 3–4
times higher risk of mortality due to CRC than individuals
without polyps (7,8). The risk of developing new lesions over time
is associated with different factors (9,10). Individuals with low-
risk adenomas (LRAs) (1–2 in number, tubular,,10 mm in size,
and with low-grade dysplasia) diagnosed during their first colo-
noscopy have a 6.9% AA risk after 5 years from the procedure,
whereas those with high-risk adenomas (HRAs) (AA and/or$3
synchronous adenomas) have a 15.5% risk after 5 years from the
procedure (11). One analysis from a population-based colono-
scopy registry showed that patients observed with large SPs at
index colonoscopy had an increased risk of metachronous large
SPs, and those with both HRAs and SPs had a considerably in-
creased risk of metachronous HRAs (12). Colonoscopy remains
the main strategy for surveillance after index polypectomy. The
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intervals between colonoscopies are based on the size, number,
and histopathology of the removed polyps. However, the current
method of risk stratification is not accurate enough because of the
lack of strong evidence (7,8,13,14).
Some research has pointed to other factors significantly
related to metachronous lesions, such as a family history of
CRC, sedentary lifestyle, smoking, and cardiovascular risk
factors of metabolic syndrome (MetS) (15–17). Furthermore,
some somatic molecular polyp characteristics have been linked
to metachronous lesions. It is well known that molecular al-
terations occur during the progression of the adenoma-
carcinoma sequence, which disturbs the cellular homeostasis.
It has been postulated that these alterations can be a pre-
disposition to new neoplasm development (18,19). In fact, the
existence of the KRAS somatic mutation has been shown to be
related to AA recurrences (20,21). For all of these reasons,
applying the integrative concept of the “etiological field effect,”
which indicates that the interaction of multiple etiological and
exogenous factors contribute to the initiation and progression
of neoplasia, could help to improve the precision of risk strat-
ification (22).
The goal of surveillance after polypectomy was to identify
metachronous high-risk lesions (HRLs), which are defined asAA,
large SPs, and/or having multiplicity ($3 adenomas and/or SPs),
for use as surrogate markers to signal the future risk of CRC
(12). Thus, knowing the predictive factors of metachronous
HRLs is essential and will improve stratification and surveillance
programs.
Our aim was to identify the predictive factors for metachro-
nous HRLs at 3 years after polypectomy. The study was con-
ducted on a cohort drawn from a population-based CRC
screening program at the index colonoscopy.We incorporated an
evaluation of the environmental and clinical factors and the
histopathological and somatic molecular changes based on the
most advanced index polyp.
METHODS
We conducted a single-center retrospective study on a cohort
that had an average risk of CRC (asymptomatic individuals
between 50 and 69 years of age) from the Barcelona CRC
Screening Program 2009–2011. The selected individuals had
all been diagnosed with HRL through colonoscopy after a fecal
immunochemistry test (OC-sensor$20 mg Hb/g of feces) and
who had undergone surveillance colonoscopy at 3 years 6 6
months after polypectomy. We recorded which cases un-
derwent more than one colonoscopy to ensure complete re-
section of polyps.
Informed consent was obtained from all patients. The bi-
ological samples were obtained from Barcelona Parc de Salut
MAR Biobank (MARBiobanc), and the study was approved by
the Hospital del Mar Clinical Research Ethics Committee (Ref.
2016S004). All colonoscopies fulfilled the standard quality policy
(23), and all endoscopists adhered to the recommended adenoma
detection rate standards.
Individuals with a personal and/or familial history of CRC
or adenoma, inflammatory bowel disease, incomplete histo-
pathological analysis of recovered polyps, and individuals who
did not provide informed consent were excluded. Individuals
who were observed to have SPs exclusively at the index colo-
noscopy were excluded because the number of SPs in such
individuals was low.
Clinical and pathological data
We assessed the data on age, sex, the fecal immunochemistry
test before colonoscopy, body mass index, smoking history,
high blood pressure (25), type 2 diabetes mellitus, and dysli-
pidemia, defined as elevated plasma cholesterol, triglycerides,
or both, or low HDL cholesterol. Data on the presence of
MetS, as defined by the World Health Organization (26),
administration of aspirin, nonsteroidal anti-inflammatory
drugs, and statins and on any chronic treatment were also
collected. Furthermore, the number of polyps, their size, lo-
cation (distal or proximal to the splenic flexure), and histo-
pathology at the basal and the surveillance colonoscopies were
recorded.
Molecular markers
The molecular study was performed on the most advanced
histological polyp in every patient. Two experienced patholo-
gists selected the relevant section of the paraffin-embedded
samples.
The genes most commonly involved in colorectal carcino-
genesis that have been linked to the risk of advanced or meta-
chronous polyps were studied based on the pathway,
chromosomes, or microsatellite instabilities. These genes were
KRAS,NRAS, BRAF,APC, TP53, FBXW7, CTNNB1, SMAD4,Ki-
67,MLH-1,CYTOKERATIN 7,CYTOQUERATIN 20, andCDX2.
DNA was extracted from formalin-fixed, paraffin-embedded
blocks of the sample using the MagCore Genomic DNA FFPE
One-Step Kit—MagCore HF 16 Plus (24,25).
Sequencing of the somaticmutation study.A sample library was
generated with a QIAseq Targeted DNA panel (Qiagen) con-
taining the coding region of the genes (see Supplementary
Digital Contents 1 and 2, Supplementary Tables 1, http://links.
lww.com/CTG/A498, and http://links.lww.com/CTG/A499).
The resulting library was sequenced on the next-generation
sequencing platform, MiSeq (Illumina, San Diego, CA), and
analyzed with the QIASeq DNA pipeline. Variants obtained
were filtered and annotated with Variant Studio v3.0 and vi-
sualized with Integrative Genomics Viewer v2.4. The average
depth of coverage was 1559 x. The frequent CRC-associated
variants in KRAS, BRAF, NRAS, APC, and TP53 genes with
variant allelic frequency ,5% were considered true variants.
Those variants with a variant allelic frequency .5% were
considered less frequent variants to minimize the probability
of false positive results.
All mutations identified were verified against a catalogue of
somatic mutations in the cancer database and VarSome (27). The
mutation nomenclature used follows the Human Genome Vari-
ation Society’s recommendations.
Immunohistochemistry technique
Tissue microarray construction. Representative hematoxylin-
eosin stained sections from polyps were prepared by 2 expe-
rienced gastrointestinal pathologists. The most histopatho-
logically advanced polyp area was selected for the construction
of the tissue microarray (TMA) blocks using a tissue arrayer.
Each case was represented in the final TMA paraffin block by 2
tissue cores, each being 1.5 mm in diameter.
Immunohistochemistry tests were performed on the
formalin-fixed paraffin-embedded TMA blocks. Sections were
cut at 4 mm and then dewaxed and rehydrated. We used an






automatized panel of Roche Ventana antibodies (Benchmarkt)
(see Supplementary Digital Contents 1 and 2, Supplementary
Tables 1, http://links.lww.com/CTG/A498, and 2 http://links.
lww.com/CTG/A499). Each marker was semiquantitatively
assessed and scored by estimating the percentage of tumor cells
showing characteristic staining.
Membrane staining for CK7 and CK20 and nuclear staining
for CDX-2 were considered positive when more than 5% of the
tumor cells showed a positive reaction for each marker; Ki-67
was considered positive when more than 5% of the nonbasal
located cells showed nuclear staining irrespective of intensity
(28,29). Loss of MLH1 expression was considered when one or
more clusters of tumor cells (minimal, focal, or multifocal) or
all dysplastic cells showed $50% non-nuclear staining, com-
pared with positive nuclear staining in normal epithelial
cells (30).
Statistical analysis
Differences between demographic, clinical, andmolecular data
among patients with and without metachronous advanced
lesions were tested with the x2 test. Multivariate logistic re-
gression analysis was conducted to identify independent pa-
rameters associated with metachronous HRLs. The results are
expressed as odds ratios (ORs) with 95% confidence intervals
(CIs). SPSS version 25 (IBM, Armonk, NY) was used for the
analyses.
RESULTS
We identified 638 individuals with HRLs at the baseline colo-
noscopy. We excluded 95 cases (14.8%) lacking surveillance
colonoscopy and 6 cases with exclusively index SPs. A total of 537
cases (85.2%) that met the inclusion and exclusion criteria (me-
dian age 60.76 5.2 years; 66% men) were analyzed. The median
surveillance colonoscopy time was 38.8 months, and the study
flow chart is presented in Figure 1.
Characteristics of the cohort included in the study are pre-
sented in Table 1. Half of the study population had had some
exposure to tobacco, and 47% had been diagnosed with dyslipi-
demia. Of note, nearly 80% of the included individuals were
overweight or obese (Figure 2).
Figure 1. Study flow chart. Patients included in the analysis. FIT, fecal immunochemical test; HRL, high-risk lesions; SP, serrated polyps; TMA, tissue
microarray.
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Table 1. Baseline characteristics
Colonoscopy Index Surveillance at 3 yr
Baseline characteristics Patients HRL No HRL
Total no. of cases N 5 537 (%) N5 103 (%) N 5 434 (%)
Age
50–59 yr 229 (42.6) 39 (17.1) 190 (82.9)
60–69 yr 308 (57.4) 64 (20.8) 244 (79.2)
Sex
Men 355 (66) 70 (19.7) 285 (80.3)
Woman 182 (44) 33 (18.2) 149 (81.8)
Cigarette smoking status
Never 268 (49.9) 40 (15.6) 228 (84.4)
Smoker/former 269 (50.1) 61 (22.7) 208 (77.3)
High blood pressure
Yes 273 (50.8) 59 (21.6) 214 (78.4)
Type 2 diabetes
Yes 79 (15.9) 18 (22.8) 61 (77.2)
Dyslipidemia
Yes 247 (46.7) 60 (24.4) 186 (75.6)
Body mass index (kg/m2)
,25 94 (19.6) 18 (19.8) 76 (80.9)
25–29 217 (45.2) 40 (18.4) 177 (81.6)
$30 169 (35.2) 33 (19.5) 136 (80.5)
Metabolic syndrome
Yes 53 (11) 14 (26.4) 39 (73.5)
Alcohol intake
Yes 76 (17.2) 18 (23.7) 58 (76.3)
NSAID treatment
Yes 65 (13.2) 13 (20) 52 (80)
Aspirin treatment
Yes 75 (15.4) 14 (18.7) 61 (81.3)
Statins treatment
Yes 201 (38.7) 42 (21) 158 (79)
More than one baseline colonoscopy
Yes 137 (25.5) 38 (27.7) 99 (72.3)
Advanced adenoma
Yes 463 (86.2) 89 (19.3) 373 (80.7)
Multiplicity ($3 polyps) 282 (52.5) 71 (25.2) 211 (74.8)
Only adenomas 228 (42.5) 61 (26.8) 167 (73.2)
Adenomas and or serrated polyps 60 (11.2) 10 (1.6) 44 (1.6)
Adenoma size $10 mm 434 (80.8) 84 (19.4) 349 (80.6)
Villous component $25% 310 (57.7) 52 (16.8) 257 (83.2)
High grade dysplasia 111 (20.7) 22 (19.8) 89 (80.2)
Location of advanced adenomas
Distal to the splenic flexure 327 (70.7) 55 (16.8) 271 (83.2)
Proximal splenic flexure 136 (29.3) 34 (25) 102 (75)
HRL, high-risk lesion; NSAID, nonsteroidal anti-inflammatory drug.






To achieve complete polyp resection, 137 cases (25.2%) re-
quired more than one colonoscopy, most of them because of
control of the piecemeal removed lesions (70%) or for complete
resection of the remaining polyps (30%).
The somatic molecular findings for the most histologically
advanced polyps in every individual are provided in Table 2. As
expected, most of the AAs had mutations in the APC gene. KRAS
mutations were more frequent in AAs (P , 0.05). In addition,
although they were not too frequent, BRAFmutations and loss of
MLH1 expression were found in proximal AAs. The mutation
data for the genes analyzed are presented in Supplementary Ta-
bles 1 and 2 (see Supplementary Digital Contents 1 and 2, http://
links.lww.com/CTG/A498, and http://links.lww.com/CTG/
A499).
At surveillance colonoscopies, 103 cases (19%) were classi-
fied as HRLs. There were 54 patients with AAs (10.1%), with 29
of the AAs (5.4%) located in the proximal colon. In 73 cases
(13.6%), we foundmultiplicity (63 cases with$3 adenomas and
10 cases with$3 adenomas plus large SPs). Nine patients (1.7%)
had large SPs in the proximal colon. The remaining 435 indi-
viduals (81.0%) had normal colonoscopy findings at 3 years
(48.9%) or had low-risk lesions (32.0%). No CRCs were
diagnosed.
Risk of advanced lesions at the surveillance colonoscopy
The univariate analysis results are reported in Tables 3 and 4.
When we evaluated the clinical factors, the patients who were
current or former smokers had a slightly but statistically sig-
nificantly increased metachronous HRL risk (OR 5 1.58, 95%
CI: 1.01–2.46) as did those with dyslipidemia (OR5 1.74, 95%
CI: 1.12–2.70). A history of dyslipidemia or high blood pressure
correlated withmultiplicity at the surveillance colonoscopy (OR
5 2.20, 95% CI: 1.32–3.67; OR 5 1.74, 95% CI: 1.05–2.91, re-
spectively). In addition, those presenting withmultiplicity at the
index colonoscopy were more than twice as likely to develop
metachronous AAs (OR 5 2.54, 95% CI: 1.36–4.74), proximal
AAs (OR5 2.46, 95% CI: 1.07–5.66), repeated multiplicity (OR
5 2.49, 95% CI: 1.45–4.28), and HRLs (OR 5 2.36, 95% CI:
1.48–3.75). The need for additional colonoscopies after the in-
dex colonoscopy correlated with increased occurrence of
metachronousAAs,multiplicity, andHRLs (OR5 1.99, 95%CI:
1.10–3.57; OR 5 1.86, 95% CI: 1.10–3.14; OR 5 1.91, 95% CI:
1.20–3.04, respectively). Of all the studied baseline character-
istics, largemetachronous SPs were only significantly associated
with the need for more than one index colonoscopy (OR5 6.56,
95% CI: 1.18–36.46), although the number of metachronous
large SPs was small. We evaluated the mutations individually
and in groups from the same polyp for the power to predict
metachronous lesions at 3 years, which turned out to be poor in
both cases. Loss of nuclear expression of the MLH1 gene at the
time of baseline colonoscopy resulted in an 8-fold increased risk
of proximal AAs (OR 5 8.68, 95% CI: 2.44–30.89) and up to a
5-fold increased risk of multiplicity (OR 5 5.02, 95% CI:
1.54–16) and HRLs (OR 5 4.59, 95% CI: 1.44–14.62) at the
follow-up colonoscopy.
Multivariate analysis
Multivariate logistic regression analysis (Table 5) confirmed
that older individuals and women had a higher risk of being
diagnosed with metachronous proximal AAs (OR5 3.59, 95%
CI: 1.29–9.93; OR 5 3.12, 95% CI: 1.31–7.69, respectively).
Dyslipidemia and smoking history were associated with a
higher risk of developing HRLs (OR5 1.68, 95%CI: 1.00–2.79;
OR 5 1.69, 95% CI: 1.00–2.86, respectively). Individuals with
index multiplicity were 3 times more likely to be diagnosed at
the 3-year surveillance of HRL (OR5 2.35, 95%CI: 1.35–4.10),
AA (OR5 3.01, 95% CI: 1.44–6.27), proximal AA (OR5 4.42,
95% CI: 1.66–11.75), and multiplicity (OR 5 2.93, 95% CI:
1.48–5.81) than those with nomultiplicity. From themolecular
somatic analysis, the multivariable analysis showed that the
expression of the MLH1 protein was significantly associated
with proximal AAs at surveillance (OR 5 15.21, 95% CI:
3.07–76.58) and the mutation in NRAS was significantly as-
sociated with any size of SP at surveillance 4.42 (95% CI:
1.31–14.91).
DISCUSSION
This study confirms that multiplicity is a strong predictor of
metachronous HRLs and also highlights the importance of
factors such as a history of smoking, dyslipidemia, older age,
female sex, and loss of MLH1 protein expression. These results
reveal the need to optimize current surveillance guideline
strategies.
At the 3-year follow-up, 19% of patients with HRL at the
index colonoscopy had metachronous HRLs. These results were
comparable with those of other studies (31). However, the
variability in HRL recurrence in published studies is high be-
cause it depends not only on individual risk factors but also on
the colonoscopy quality and the subsequent polyps’ miss rate
(MR) (9,32,33). In our cohort, we estimated a 13%MR forAAs, a
Figure 2. Predictive factors of metachronous overall lesions. Multivariate analysis. AA, advanced adenoma; HBP, high blood pressure; OR, odds ratio.
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proportion higher the 9%MR published in the meta-analysis by
Zhao et al. (34). Our MR was likely overestimated because we
obtained it from surveillance colonoscopies performed to en-
sure complete resection (46).
Older age and female sex were robust predictors of meta-
chronous proximal AAs (OR 5 3.59, 95% CI: 1.29–9.93; OR 5
3.12, 95% CI: 1.31–7.69, respectively). Older age has been iden-
tified as an independent HRL risk factor (9,35), especially for
HRLs in the proximal colon (36). This might be because of de-
creased immunity and genetic variations that occur with ad-
vancing age (35). The Clinical Outcomes Research Initiative
endoscopy database provides the opportunity to study the dif-
ferences in polyps and tumors with differences in age and sex.
Using this, we found that women have a greater tendency of
developing right-sided polyps. Indeed, hormonal factors may
explain a large percentage of the metachronous right-sided AAs
observed inwomen (37) because estrogen exposure is a protective
factor against the Microsatellite Instable high phenotype, which
often accompanies right-sided tumors (38). Therefore, it is nec-
essary to emphasize that special attention must be given in the
detection of proximal lesions in women older than the age of 60
years.
There is limited information about the role of each of the
components of MetS in metachronous HRL development (16).
Nevertheless, we found a higher proportion of new HRLs at
surveillance colonoscopy in patients with dyslipidemia; up until
now, themolecularmechanismbehind this is notwell understood
(38,39).
Likewise, carcinogenic compounds in tobacco, mainly aro-
matic amines, can cause mutations in genes implicated in CRC,
such as KRAS and BRAF (40). In a retrospective study, higher
nicotine levels between the index and follow-up colonoscopies
were correlated with metachronous colorectal neoplasia risk
(41). These findings have important public health implications
because they show that improving the plasma levels of
cholesterol/triglycerides and giving up cigarette smoking would
be effective measures for preventing colorectal metachronous
polyps.
In our series, exposure to tobacco and the presence of dysli-
pidemia had a higher risk of global metachronous HRL, whereas
older age, female sex, and loss of MLH1 expression were signifi-
cantly associated with HRLs on the right side (36,42). Thus, our
results could suggest that genetic factors have a greater effect on
the proximal colon, whereas environmental factors have a more
global effect (36,42).
Some characteristics found in index polyps are indicative of
an increased risk of metachronous lesions. However, these
findings are sufficiently helpful for planning early surveillance
strategies, most likely because their effect could depend on la-
tency time. We did not find any histological characteristics that
increased metachronous HRL risk. Nonetheless, we report that
multiplicity on index colonoscopy was a powerful predictor of
HRL recurrence, possibly owing to genetic imbalance of cell
proliferation in some individuals, which could lead to acceler-
ated carcinogenesis on normal mucosa. Therefore, it is impor-
tant to ensure that proper surveillance is performed on these
individuals(43,44,46).
In addition, we found thatNRASmutations predicted the risk
of SPs of any size 3 years after the polypectomy, and the loss of
Table 2. Molecular baseline characteristics
Mutation Patients %
KRAS (n5 441)
Wild type#5% 278 63
Mutation .5% 163 37
BRAF (n5 444)
Wild type#5% 425 95.7
Mutation .5% 19 4.3
NRAS (n5 444)
Wild type#5% 429 96.6
Mutation .5% 15 3.4
APC (n 5 434)
Wild type#5% 50 11.5
Mutation .5% 384 88.5
TP53 (n5 436)
Wild type#5% 345 79.1
Mutation .5% 91 20.9
CTNNB1 (B-catenin) (n 5 408)
Wild type#5% 391 95.8
Mutation .5% 17 4.2
SMAD4 (n 5 411)
Wild type#5% 400 97.3
Mutation .5% 11 2.7
FBXW7 (n 5 407)
Wild type#5% 364 89.4
Mutation .5% 43 10.6
MLH1 (n5 455)
Normal expression 443 97.4
Loss nuclear expression $50% 12 2.6
CDX2 (n5 455)
Normal expression 259 56.9
Loss of any nuclear expression 196 36.5
Cytokeratin 7 (n 5 446)
Normal expression 396 88.8
Cytoplasmatic expression 50 11.2
Cytokeratin 20 (n5 440)




Ki-67 (n 5 332)
Normal expression 2 0.6
Nuclear expression 330 99.4
APC 1 KRAS 142 32.7
APC 1 KRAS 1 TP53 37 8.5
APC 1 KRAS 1 NRAS 5 1.1






MLH1 protein expression was associated with proximal AA.
Limited data exist about themolecular profile of index polyps as a
predictive factor of metachronous lesions. Because several such
polyps represent early mutational changes, they could prove
useful in histological classification efforts, apart from their con-
ventional use as carcinogenesis predictors. As expected, BRAF
mutations were uncommon, although no patients with SPs were
analyzed. Nevertheless, we found that 4% of patients exhibited
BRAF mutation and loss of MLH1 protein expression. These
polyps could reflect mixed polyps or serrated polyps mistakenly
classified as adenomas. Three yearsmay have been a too short of a
period to identify molecular changes to predict recurrence (19).
Juarez et al. found that polyps with KRASmutations had a 2-fold
higher risk of metachronous advanced lesions. Although we
could not replicate this finding in our series, we found that KRAS
mutations were useful for diagnosing HRL. This discrepancy
could be because the cohort was different and that they analyzed
all polyps, whereas we analyzed the most advanced polyp of each
individual.
This study has several strengths. The cohort was homogenous,
drawn from a CRC population screening program, and although
this was a retrospective study, baseline colonoscopies were
Table 3. Predictive factors of metachronous overall lesions (univariate analysis)
Baseline characteristics Polyps Adenoma Serrated lesion
Variable n OR (95% CI) n OR (95% CI) n OR (95% CI)
Age .60 yr 164 1.25 (0.89–1.77) 151 1.21 (0.86–1.72) 18 0.49 (0.26–0.91)
Gender (female) 90 0.90 (0.63–1.29) 80 0.82 (0.57–1.17) 17 1.24 (0.65–2.35)
Smoker/former 145 1.23 (0.88–1.74) 133 1.19 (0.84–1.68) 28 1.85 (0.96–3.55)
High blood pressure 151 1.39 (0.99–1.95) 142 1.47 (1.04–2.07) 19 0.70 (0.37–1.31)
Type 2 diabetes 45 1.28 (0.79–2.07) 43 1.36 (0.84–2.20) 7 1.11 (0.47–2.58)
Dyslipidemia 142 1.61 (1.14–2.27) 136 1.80 (1.27–2.55) 22 1.18 (0.63–2.19)
Body mass index $30 88 1.03 (0.80–1.32) 79 1.00 (0.78–1.29) 15 1.10 (0.69–1.73)
Metabolic syndrome 35 1.92 (1.05–3.5) 34 2.14 (1.18–3.87) 3 0.64 (0.19–2.16)
.1 colonoscopy 85 1.80 (1.21–2.68) 80 1.82 (1.23–2.70) 18 2.13 (1.13–4.02)
$3 polyps 173 2.41 (1.70–3.42) 164 2.60 (1.83–3.69) 28 1.62 (0.85–3.07)
AA 228 0.61 (0.37–1.01) 210 0.62 (0.38–1.02) 37 0.83 (0.35–1.93)
Proximal AA 82 1.70 (1.14–2.54) 76 1.65 (1.11–2.45) 16 1.78 (0.93–3.42
Adenoma size
$10 mm 208 0.51 (0.33–0.80) 192 0.55 (0.35–0.85) 33 0.68 (0.33–1.39)
$20 mm 67 1.10 (0.73–1.64) 60 1.01 (0.67–1.51) 16 1.96 (1.02–3.75)
Villous component$25% 172 0.82 (0.58–1.17) 138 0.78 (0.55–1.10) 25 0.95 (0.51–1.76)
High grade dysplasia 56 0.95 (0.63–1.45) 52 0.97 (0.64–1.48) 10 1.12 (0.54–2.35)
KRAS mutation 86 1.04 (0.70–1.54) 80 1.07 (0.73–1.58) 11 0.73 (0.35–1.53)
NRAS mutation 8 1.05 (0.37–2.96) 7 0.95 (0.34–2.65) 4 3.96 (1.20–13.07)
BRAF mutation 10 1.03 (0.41–2.59) 9 0.98 (0.39–2.47) 3 2.21 (0.61–7.99)
APC mutation 198 1.07 (0.59–1.94) 182 0.98 (0.54–1.77) 31 1.01 (0.34–3.01)
TP53 mutation 45 0.87 (0.55–1.39) 42 0.91 (0.57–1.45) 7 0.94 (0.39–2.21)
CTNNB1 mutation 11 1.71 (0.62–4.72) 10 1.57 (0.58–4.22) 3 2.47 (0.67–9.08)
SMAD4 mutation 5 0.74 (0.22–2.48) 4 0.61 (0.17–2.10) 2 2.38 (0.49–11.46)
MLH1 8 1.92 (0.57–6.46) 8 2.26 (0.67–7.61) 2 2.39 (0.50–11.37)
CDX2 127 0.82 (0.57–1.20) 118 0.87 (0.59–1.25) 15 0.52 (0.26–1.03)
Cytokeratin 7 25 0.95 (0.52–1.71) 23 0.93 (0.51–1.68) 4 1.13 (0.38–3.37))
Cytokeratin 20 195 1.19 (069–203) 180 1.15 (0.67–1.97) 31 1.80 (0.53–6.08)
Ki67 161 — 151 — 21 0.07 (0.004–1.13)
APC and KRAS 74 1.01 (0.67–1.51) 68 1.00 (0.67–1.50) 9 0.67 (0.31–1.47)
APC, KRAS, and p53 19 0.97 (0.49–1.91) 19 1.16 (0.59–2.28) 2 0.62 (0.14–2.68)
APC, KRAS, and NRAS 2 0.60 (0.10–3.67) 2 0.71 (0.11–4.33) 1 2.89 (0.31–26.59)
Significant values are represented in bold.
AA, advanced adenoma; CI, confidence interval; OR, odds ratio.





Predictors of Metachronous Risk Polyps 7
performed following an identical protocol of quality standards.
Moreover, the integrity of both resections and polyp pathology
analyses was ensured via second-look colonoscopies when it was
deemed necessary, and the surveillance colonoscopy was performed
at 3 years using the same quality standards. Finally, clinical in-
formation was obtained from computerized medical records. Thus,
ours is a study with reliable results involving exhaustive analyses of
clinical, endoscopic, and molecular factors associated with advanced
metachronous lesions at 3 years after polypectomy.
This study also has certain limitations. Some clinical factors asso-
ciatedwith the risk ofmetachronous lesions, such as diet and physical
activity, were not studied, and theymay be relevant. Furthermore, the
CpG island methylator phenotype and microsatellite instability were
not determined. Although these results would have been interesting,
we instead analyzed BRAFmutations andMLH1 expression that also
reflect the serrated pathway, although the correlation is not always
100%. Likewise, a greater number of cases included in the study could
have helped to obtain more relevant results.
Table 4. Predictive factors of metachronous risk lesions characterized by AA, multiplicity (‡3 polyps), high-risk lesion (AA and/or
multiplicity), and advanced serrated polyps (univariate analysis)
Baseline characteristics Surveillance colonoscopy
Variable
AA Proximal AA Multiplicity HRL Large SPs (‡10 mm)
n OR (95% CI) n OR (95%CI) n OR (95%CI) n OR (95% CI) n OR (95% CI)
Age .60 yr 34 1.29 (0.72–2.31) 23 3.01 (1.18–7.40) 45 1.22 (0.73–2.03) 64 1.36 (0.87–2.12) 3 0.85(0.17–4.28)
Gender (female) 22 1.40 (0.78–2.5) 15 2.22 (1.04–4.76) 22 0.82 (0.48–1.40) 33 0.90 (0.48–1.44) 9 2.12 (0.57–1.44)
Smoker/former 31 1.45 (0.81–2.61) 12 0.70 (0.32–1.52) 42 1.44 (0.87–2.40) 61 1.58 (1.01–2.46) 10 1.44 (0.53–3.87)
High blood pressure 23 0.68 (0.38–1.20) 13 0.76 (0.36–1.63) 46 1.74 (1.05–2.91) 58 1.36 (0.87–2.10) 4 2.00 (0.36–11.05)
Type 2 diabetes 7 0.83 (0.36–1.92) 1 0.19 (0.02–1.46) 13 1.28 (0.66–2.47) 18 1.31 (0.73–2.33) 1 1.23 (0.14–10.81)
Dyslipidemia 27 1.18 (0.67–2.07) 14 1.1 (0.52–2.32) 46 2.20 (1.32–3.67) 60 1.74 (1.12–2.70) 1 0.24 (0.02–2.10)
Body mass index $30 17 1.03 (0.68–1.58) 8 0.94 (0.53–1.66) 24 1.05 (0.73–1.51) 33 1.00 (0.72–1.37) 1 0.72 (0.21–2.44)
Metabolic syndrome 40 1.23 (0.49–3.07) 1 0.34 (0.46–2.60) 11 1.77 (0.86–3.65) 14 1.69 (0.87–3.26) 0 —
.1 colonoscopy 21 1.99 (1.10–3.57) 12 2.12 (0.99–4.58) 27 1.86 (1.10–3.14) 38 1.91 (1.20–3.04) 4 6.56 (1.18–36.46)
$3 polyps 39 2.54 (1.36–4.74) 21 2.46 (1.07–5.66) 52 2.49 (1.45–4.28) 71 2.36 (1.48–3.75) 5 5.32 (0.61–46.03)
AA 45 0.76 (0.35–1.64) 24 0.74 (0.27–2.02) 63 0.99 (0.48–2.04) 89 1.08 (0.57–2.06) 5 0.76 (0.08–6.65)
Proximal AA 16 1.26 (0.68–2.35) 9 1.33 (0.59–3.00) 24 1.53 (0.89–2.60) 34 1.56 (0.97–2.49) 2 1.75 (0.31–9.72)
Adenoma size
$10 mm 42 1.00 (0.53–1.88) 21 0.72 (0.25–1.40) 57 1.44 (0.79–2.59) 84 1.25 (0.99–1.57) 4 0.36 (0.07–1.83)
$20 mm 15 1.28 (0.68–2.41) 21 1.02 (0.42–2.46) 19 1.16 (0.66–2.05) 27 1.23 (0.75–2.02) 4 1.60 (0.28–8.88)
Villous component$25% 29 0.83 (0.47–1.46) 14 0.66 (0.31–1.39) 34 0.59 (0.36–0.97) 52 0.69 (0.45–1.07) 4 1.31 (0.23–7.27)
High grade dysplasia 13 1.23 (0.63–2.40) 6 0.99 (0.39–2.49) 13 0.80 (0.42–1.52) 22 1.08 (0.63–1.82) 2 1.86 (0.33–10.35)
KRAS mutation 15 0.81 (0.42–1.55) 8 0.66 (0.28–1.55) 21 0.88 (0.50–1.56) 34 1.21 (0.74–1.97) 3 2.58 (0.42–15.68)
NRAS mutation 2 1.34 (0.29–6.14) 2 2.37 (0.50–11.07) 2 0.96 (0.21–4.37) 3 1.07 (0.25–3.38) 0 —
BRAF mutation 3 1.70 (0.47–6.09) 3 3.11 (0.84–11.43) 4 1.75 (0.56–5.46) 5 1.58 (0.55–4.52) 3 —
APC mutation 39 1.02 (0.38–2.72) 22 0.70 (0.23–2.13) 51 0.80 (0.35–1.81) 74 1.05 (0.49–2.26) 35 0.44 (0.04–4.10)
TP53 mutation 8 0.77 (0.34–1.72) 5 0.80 (0.29–2.19) 12 0.83 (0.18–3.73) 14 0.73 (0.39–1.38) 8 —
CTNNB1 mutation 1 0.51 (0.06–4.00) 0 — 2 0.93 (0.47–1.84) 2 0.56 (0.12–2.54) 3 6.72 (0.68–67.77)
SMAD4 mutation 2 1.94 (0.40–9.28) 1 1.49 (0.18–12.12) 2 1.39 (0.29–6.60) 2 0.96 (0.20–4.53) 1 —
MLH1 3 3.09 (0.80–11.8) 4 8.68 (2.44–30.89) 5 5.02 (1.54–16) 6 4.59 (1.44–14.62) 3 —
CDX2 25 0.89 (0.48–1.65) 14 0.74 (0.34–1.59) 35 1.07 (0.61–1.86) 48 0.92 (0.57–1.48) 18 0.44 (0.07–2.66)
Cytokeratin 7 6 1.28 (0.51–3.20) 4 1.39 (0.46–4.22) 4 0.51 (0.17–1.48) 8 0.77 (0.34–1.71) 4 —
Cytokeratin 20 39 1.09 (0.44–2.71) 2 2.17 (0.50–9.43) 53 1.31 (0.56–3.03) 73 1.00 (0.51–1.98) 4 —
Ki67 0 — 0 — 1 0.12 (0.01–1.94) 56 0.19 (0.01–3.18) 1 —
APC and KRAS 14 0.93 (0.48–1.82) 7 0.71 (0.29–1.72) 19 0.96 (0.53–1.72) 30 1.25 (0.76–2.07) 12 3.04 (0.50–18.52)
APC, KRAS, and p53 4 1.04 (0.35–3.08) 2 0.82 (0.18–3.62) 5 0.98 (0.36–2.64) 7 1.00 (0.42–2.37) 3 —
APC, KRAS, and NRAS 1 2.20 (0.24–20.1) 1 3.82 (0.41–35.4) 2 4.31 (0.70–26.38) 2 2.91 (0.48–17.74) 2 —
Significant values are represented in bold.
AA, advanced adenoma; CI, confidence interval; OR, odds ratio; HRL, high-risk lesion; SP, serrated polyps.






In conclusion, these results suggest that the ability to identify
groups at risk of metachronous lesions remains challenging, as
does the formulation of best follow-up recommendations.
Older age, female sex, smoking status, dyslipidemia, and
baseline multiplicity significantly increased the risk of new ad-
vanced lesions at 3 years after polypectomy. The clinical
guidelines for patient surveillance after index polypectomy
should consider incorporating these clinical factors to person-
alize surveillance recommendations. Because no cancer was
diagnosed at surveillance, we suggest that follow-up should be
performed at 5 years after the procedure if the individuals do not
present with risk predictive factors. Regarding MLH1 expres-
sion, we suggest examining it in all patients when conducting
proximal HRL surveillance because it would be a cost-effective
strategy because of the low price of the MLH1 immunohisto-
chemistry technique.
Future studies involving larger cohorts could further confirm
these findings.
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Study Highlights
WHAT IS KNOWN
3 The risk of developing new advanced lesions is associated
with different factors.
3 Clinical follow-up recommendations are lacking in strong
evidence, and surveillance strategies are based only on the
size, number, and pathologic characteristics of the removed
index polyps.
3 Knowing clinical and molecular predictive factors of
metachronous risk lesions would provide better risk
stratification and improve surveillance programs.
WHAT IS NEW HERE
3 Results regarding clinical, endoscopic, andmolecular factors
associated with risk metachronous lesions at 3 years.
3 This study confirms that multiplicity is a strong predictor of
metachronous HRLs, besides the relevance such factors as a
history of smoking, dyslipidemia, older ager, female sex, and
loss of MLH1 protein expression.
3 These results expose the need to optimize current
surveillance guidelines strategies.
TRANSLATIONAL IMPACT
3 Wesuggest following upat 5 years if individuals do not present
with clinical risk predictive factors.
3 We propose examining patients with HRLs considering that it
would be a cost-effective strategy because of low price of the
MLH1 immunohistochemistry technique.
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Table 5. Predictive factors of metachronous risk lesions (multivariate analysis)
Basal characteristics
Surveillance colonoscopy
AAs Proximal AA ‡3 polyps High risk lesions (AA and/or multiplicity) Large serrated lesions
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 60–69 1.55 (0.76–3.14) 3.59 (1.29–9.93) 1.34 (0.71–2.54) 1.51 (0.87–2.60) 0.91 (0.27–3.21)
Gender (female) 2 (1–4) 3.12 (1.31–7.69) 1.21 (0.60–2.45) 1.40 (0.77–2.53) 2.84 (0.73–11.05)
Smoker/former 1.74 (0.85–3.58) 0.95 (0.38–2.33) 1.64 (0.85–3.20 1.69 (1.00–2.86) 4.82 (1.05–22.02)
Dyslipidemia 1.03 (0.53–2.02) 0.86 (0.37–2.01) 2.47 (1.33–4.57) 1.68 (1.00–2.79) 0.71 (0.20–2.45)
$3 polyps 3.01 (1.44–6.27) 4.42 (1.66–11.75) 2.93 (1.48–5.81) 2.35 (1.35–4.10) 3.70 (0.81–16.83)
.1 colonoscopy 1.21 (0.56–2.57) 1.82 (0.72–4.64) 1.74 (0.90–3.38) 1.64 (0.92–2.93) 3.64 (1.16–11.34)
Adenoma size $20 mm 0.92 (0.41–2.09) 0.69 (0.23–2.02) 0.94 (0.46–1.94) 1.04 (0.56–1.93) 2.33 (0.68–8.8.03)
NRAS 1.23 (0.25–6.07) 1.87 (0.35.9.93) 1.05 (0.18–5.96) 1.08 (0.26–4.49) 4.45 (0.43–46.51)
MLH1 3.06 (0.57–16.21) 15.21 (3.07–76.58) 4.09 (0.88–18.95) 4.03 (0.99–16.43)
AA, advanced adenoma; CI, confidence interval; OR, odds ratio.





Predictors of Metachronous Risk Polyps 9
REFERENCES
1. AtkinWS,Morson BC, Cuzick J. Long-term risk of colorectal cancer after
excision of rectosigmoid adenomas. N Engl J Med 1992;326(10):658–62.
2. Winawer SJ, Zauber AG, HoMN, et al. Prevention of colorectal cancer by
colonoscopic polypectomy. N Engl J Med 1993;329(27):1977–81.
3. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum:
Review and recommendations from an expert panel. Am J Gastroenterol
2012;107(9):1315–29.
4. East JE, AtkinWS, BatemanAC, et al. British Society of Gastroenterology
position statement on serrated polyps in the colon and rectum. Gut 2017;
66(7):1181–96.
5. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy
and long-termprevention of colorectal-cancer deaths.NEngl JMed 2012;
366(8):687–96.
6. Arditi C, Peytremann-Bridevaux I, Burnand B, et al. Appropriateness of
colonoscopy in Europe (EPAGE II) Screening for colorectal cancer.
Endoscopy 2009;41:200–8.
7. He X, Hang D, Wu K, et al. Long-term risk of colorectal cancer after
removal of conventional adenomas and serrated polyps.
Gastroenterology 2020;158(4):852–61.e4.
8. Song M, Emilsson L, Bozorg SR, et al. Articles. Risk of colorectal cancer
incidence and mortality after polypectomy : A Swedish record-linkage
study. Lancet Gastroenterol Hepatol 2020;1253(20):1–11.
9. Mart́ınez ME, Baron JA, Lieberman DA, et al. A pooled analysis of
advanced colorectal neoplasia diagnoses after colonoscopic polypectomy.
Gastroenterology 2009;136(3):832–41.
10. van Heijningen EB, Lansdorp-Vogelaar I, Kuipers EJ, et al. Features of
adenoma and colonoscopy associated with recurrent colorectal neoplasia
based on a large community-based study. Gastroenterology 2013;144(7):
1410–8.
11. AnaBM,MercedesAM,AdánMerinoL, et al. Factors related to colorectal
cancer in advanced adenomas and serrated polyps. Eur J Gastroenterol
Hepatol 2018;30(11):1337–43.
12. Anderson JC, Butterly LF, Robinson CM, et al. Risk of metachronous
high-risk adenomas and large serrated polyps in individuals with serrated
polyps on index colonoscopy: Data from the New Hampshire
Colonoscopy Registry. Gastroenterology 2018;154(1):117–27.e2.
13. Bonnington SN. Surveillance of colonic polyps: Are we getting it right?
World J Gastroenterol 2016;22(6):1925.
14. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy
surveillance after screening and polypectomy: A consensus update by the
US Multi-Society Task Force on Colorectal Cancer. Gastroenterology
2012;143(3):844–57.
15. Jacobs ET, Ahnen DJ, Ashbeck EL, et al. Association between body mass
index and colorectal neoplasia at follow-up colonoscopy: A pooling study.
Am J Epidemiol 2009;169(6):657–66.
16. Ashbeck EL, Jacobs ET, Martinez ME, et al. Components of metabolic
syndrome and metachronous colorectal neoplasia. Cancer Epidemiol
Biomarkers Prev 2009;18(4):1134–43.
17. Flood A, Mai V, Pfeiffer R, et al. Elevated serum concentrations of insulin
and glucose increase risk of recurrent colorectal adenomas.
Gastroenterology 2007;133(5):1423–9.
18. Gupta S, Sun H, Yi S, et al. Molecular markers of carcinogenesis for risk
stratification of individuals with colorectal polyps: A case-control study.
Cancer Prev Res 2014;7(10):1023–34.
19. Berger AW, Raedler K, Langner C, et al. Genetic biopsy for prediction of
surveillance intervals after endoscopic resection of colonic polyps: Results
of theGENESIS study. United EuropeanGastroenterol J 2018;6(2):290–9.
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